603259.SS Earnings — WuXi AppTec Co., Ltd.
SHH
Updated
When is 603259.SS's next earnings date?
WuXi AppTec Co., Ltd. (603259.SS) has not announced its next earnings date yet. Its most recent earnings report was on Monday, October 26, 2026.
How did 603259.SS do in its last earnings report?
In its most recent report on Oct 26, 2026, WuXi AppTec Co., Ltd. posted EPS of $2.83 versus the $2.91 estimate, a miss of 2.8%. Revenue was $15.61B against a $15.97B estimate.
How much does 603259.SS stock move after earnings?
603259.SS beat EPS estimates in 1 of its last 2 reported quarters.
About WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People’s Republic of China.
🤖 AI Earnings Analysis
603259.SS combines a 42.21% profit margin with a 19.3× P/E, suggesting strong profitability at a moderate valuation; no recent news or earnings data was provided.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-26 | 2.91 | 2.83 | -2.75% | $15.61B | ❌ Miss | — | — | — | |
| 2026-08-03 | 1.56 | 2.16 | — | $16.34B | ✅ Beat | — | — | — |
Showing last 2 quarters.